Updates in PV treatment: the efficacy of ropeginterferon alfa-2b

Tariq Mughal, MD, FRCP, FACP, Tufts University School of Medicine, Boston, MA, and Buckingham University Medical School, Buckingham, UK, discusses therapeutic advancements for polycythemia vera (PV), which have focused on reducing thrombosis—a factor associated with significant morbidity in these patients. Dr Mughal highlights the development of long-acting interferons, such as ropeginterferon alfa-2b, which shows promise in reducing thrombotic events and transfusion requirements, and potentially modifies the disease by lowering the JAK2 allelic burden. This interview took place virtually as part of the 16th International Congress on Myeloproliferative Neoplasms (MPNs) in New York City, NY. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.